Moderna Inc., pleased with the results of its phase I clinical trial in Africa, which is the first of its kind, for its HIV vaccination that is currently in development, according to a press release.
Moderna, a Massachusetts company, was pioneered when it discovered a COVID-19 vaccine at the start of the epidemic. This reaction was driven by the mRNA technology. Moderna''s technology might be rapidly scaled and rapidly modified than conventional vaccine manufacturing methods if the virus is mutated in a very different form.
The company is now focusing its attention on developing other vaccinations that had taken a backseat during the epidemic.
An mRNA vaccine to tackle HIV
Moderna initiated the first human trial of its HIV vaccine in the United States in which it usedeOD-GT8 60mer, a component of the HIV RNA sequence, as a recombinant protein. The immunogen elicits a specific type of B cell which then leads to the development of broadly neutralizing antibodies (bnAbs) which are considered an important objective of an effective HIV vaccine. According to a press release, the vaccine was tested to be safe and evoked an immune response in
The phase I study in Africa is funded by the International AIDS Vaccine Initiative (IAVI) and aims to replicate the results of the US trial in the African population. The clinical substance, theeOD-GT8 60mer, is a viral gene that contains a portion of the infection but does not cause the infection.
The aim of the trial is to make sure all participants receive the vaccination for a period of six months to ensure the vaccine is safe, while their immune response will be investigated in detail at a molecular level to ensure the target response. According to a press release, the researchers working at various medical institutions in Kenya will confirm the outcome.
"We are grateful for the opportunity to work with researchers and scientists from communities devastated by HIV," says Moderna''s CEO. Moderna''s HIV vaccination development program, combined with our portfolio of COVID-19, Zika, and Nipah programs, will further develop four of the 15 key vaccination programs we expect to develop by 2025, aimed at chronic diseases.